News
Academy
Publications
Media
Conferences
Columns
Resources
Webcasts
Subscribe

|Articles|September 16, 2013

What is Misunderstood about RBM

A conversation with Marc Buyse, founder of CluePoints on risk based monitoring in clinical trials

A conversation with Marc Buyse, founder of CluePoints on risk based monitoring in clinical trials

This video is part of a series of conversations on risk-based monitoring. Click here to see all the videos.

For more videos of Marc Buyse, see also:

Intelligent Statistical Monitoring Results

Intelligent Statistical Monitoring Study Signals

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related Content

© weyo - © weyo - stock.adobe.com

Vaccine Trials at an Inflection Point: Operational, Regulatory, and Public Trust Challenges

ByAndy Studna, Senior Editor

June 8th 2026

ACT Brief: Cross-Asset Site Partnerships, Vaccine Trial Standardization, and Ovarian Cancer Care Gaps

ByAndy Studna, Senior Editor

June 8th 2026

A Shot in the Arm to Traditional Vaccine Trial Strategy

June 5th 2026

SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years

ByLiz Beatty,Andy Studna, Senior Editor

June 5th 2026

ACT Brief: Site-First Technology Strategy, AI Data Harmonization Architecture, and Obesity Trial Retention

ByAndy Studna, Senior Editor

June 5th 2026

Trending on Applied Clinical Trials Online

The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck

ACT Brief: Cross-Asset Site Partnerships, Vaccine Trial Standardization, and Ovarian Cancer Care Gaps

SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years

Patient Engagement Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention

A Shot in the Arm to Traditional Vaccine Trial Strategy